Evidence map›Paper›PMID 41578352›Full record

ArticleActa neuropathologica communications2026

Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma.

Ben Jin, Hao Hu, Yanhua Lu, Xia Tian, Guanghui Hu, Jingjing Xu, Xingqi Wu, Long Zhang, Juxiang Chen, Miaoxia He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ben JinDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Hao HuDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Yanhua LuDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Xia TianDepartment of Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Guanghui HuDepartment of Plastic and Reconstructive Surgery, School of Medicine, Shanghai Fourth People's Hospital, Tongji University, Shanghai, 200434, China.
Jingjing XuDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Xingqi WuDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Long ZhangDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Juxiang ChenDepartment of Neurosurgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. juxiangchen@smmu.edu.cn.
Miaoxia HeDepartment of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China. miaoxiahe@smmu.edu.cn.ORCID 0000-0001-5666-6889

Funding

National Natural Science Foundation of China 82272715Shanghai Science and Technology Committee of China 18411963000
6 · The paper itself

Abstract

backgroundMeningiomas are the most common primary intracranial tumor in adults and systemic therapy is urgently needed for high-grade fatal tumors and those cannot be completely removed by surgery. Multiomics studies have established a molecular classification system in addition to the grading system by the World Health Organization, and SWI/SNF-related BAF chromatin remodeling complex subunit B1 (SMARCB1) mutation was enriched in the immunogenic subgroup. Meningiomas are myeloid-dominant tumors with abundant and unevenly distributed CD163

methodsA study cohort consisting of 113 patients was established to examine the association between serum immune profile and relapse-free survival. The second study cohort containing 35 patients across different WHO grades and disease states was established to validate and identify immune cell infiltration in the tumor microenvironment. Spatial distribution of immune cells was accessed by immunohistochemistry staining and multiplex immunofluorescence staining. Single-cell RNA sequencing (RNA-seq), bulk RNA-seq and whole exon seq data were analyzed to identify genomic signatures that represent the immunogenic subgroup of meningiomas. Public databases were explored to determine a potential mechanistic link between SMARCB1 and the interleukin-17/colony stimulating factor 1 (IL-17/CSF1) axis.

resultsSerum IL-17 A and IL-5 levels favored a good prognosis of meningioma. CD163

conclusionThe findings reveal that the infiltration of CD163

Indexed as

Meningeal NeoplasmsMeningiomaSMARCB1 ProteinTumor MicroenvironmentAdultAgedAntigens, CDCD163 AntigenFemaleHumansMacrophage Colony-Stimulating FactorMacrophagesMaleMiddle AgedAntigens, CDCD163 AntigenMacrophage Colony-Stimulating FactorSMARCB1 ProteinSMARCB1 protein, humanCSF1IL-17 signaling pathwayMeningiomaSMARCB1

Identifiers

PMID41578352
PMCPMC12958713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.